Pay in 4 interest-free payments of $7.25 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
It would not create the same approval that applies to a standard prescription drug sold nationwide
The Certificate of Analysis (COA) for this product is available for download: View COA / HPLC / MS Report
Zelsuvmi, which is approved for individuals one year and older, is expected to be available in the U.S
In human clinical use, reported side effects are generally mild and transient: Mild injection site redness or discomfort (resolves within hours) Transient nausea in some patients, particularly early in the protocol Mild dizziness or light-headedness (rare, typically dose-related) Temporary fatigue in the first few days (often a sign of active tissue remodeling) No significant systemic toxicity, organ damage, hormonal suppression, or addiction potential has been documented in the published literature
